Aktuelle Aussendungen (42 Treffer in 60 Monaten)
Nächste Seite
EANS-Adhoc: Oxygen Biotherapeutics Reports Second Quarter FY2012 Financial Results. -Management to host teleconference to discuss financial results on December 19-
OTE0001 | 17. Dez. 2011, 12:39 | Channel: Finanzen | Aussender: Oxygen Biotherapeutics Inc.
EANS-Adhoc: Oxygen Biotherapeutics Announces Registered Financing for up to $7.5 million in Gross Proceeds
OTE0009 | 9. Dez. 2011, 19:06 | Channel: Finanzen | Aussender: Oxygen Biotherapeutics Inc.
EANS-Adhoc: Oxygen Biotherapeutics macht Sekundärkotierung an SIX rückgängig
OTS0003 | 28. Okt. 2011, 06:31 | Channel: Finanzen | Aussender: Oxygen Biotherapeutics Inc.
EANS-Adhoc: Oxygen Biotherapeutics to Voluntarily Withdraw Secondary Listing from SIX Swiss Stock Exchange
OTE0002 | 28. Okt. 2011, 06:31 | Channel: Finanzen | Aussender: Oxygen Biotherapeutics Inc.
EANS-Adhoc: Oxygen Biotherapeutics Names Dr. Ronald Blanck Chairman of the Board
OTE0001 | 1. Okt. 2011, 10:16 | Channel: Finanzen | Aussender: Oxygen Biotherapeutics Inc.
EANS-Adhoc: Oxygen Biotherapeutics Reports First Quarter FY2012 Financial Results and Announces Conference Call and Webcast for Shareholders
OTE0001 | 20. Sept. 2011, 06:31 | Channel: Finanzen | Aussender: Oxygen Biotherapeutics Inc.
EANS-Adhoc: Oxygen Biotherapeutics Announces Dismissal of Chris J. Stern as CEO and Appointments of Michael B. Jebsen as Interim CEO and Rene Eckert as Interim Chairman. -Oxygen Biotherapeutics to reschedule its 2011 General Annual Meeting of Stockholders-
OTE0003 | 25. Aug. 2011, 07:19 | Channel: Finanzen | Aussender: Oxygen Biotherapeutics Inc.
EANS-Adhoc: Oxygen Biotherapeutics und Aurum Biosciences unterzeichnen Absichtserklärung zur Erforschung von Oxycyte® PFC für Imaging und therapeutische Interventionen bei akutem ischämischem Hirnschlag.
OTS0001 | 25. Juli 2011, 06:31 | Channel: Finanzen | Aussender: Oxygen Biotherapeutics Inc.
EANS-Adhoc: Oxygen Biotherapeutics and Aurum Biosciences Sign Letter of Intent to Explore the Use of Oxycyte® PFC for Imaging and Therapeutic Intervention of Acute Ischemic Stroke
OTE0001 | 25. Juli 2011, 06:31 | Channel: Finanzen | Aussender: Oxygen Biotherapeutics Inc.
EANS-Adhoc: Oxygen Biotherapeutics Reports Financial Results for Fiscal Year 2011
OTE0001 | 15. Juli 2011, 06:31 | Channel: Finanzen | Aussender: Oxygen Biotherapeutics Inc.
EANS-Adhoc: Oxygen Biotherapeutics Inc. / Ausdehnung der Phase IIb für STOP TBI nach Indien bewilligt.
OTS0003 | 7. Juni 2011, 06:31 | Channel: Finanzen | Aussender: Oxygen Biotherapeutics Inc.
EANS-Adhoc: Oxygen Biotherapeutics Receives Approval to Expand Phase IIb Trials with Oxycyte® PFC for Traumatic Brain Injury into India
OTE0002 | 7. Juni 2011, 06:31 | Channel: Finanzen | Aussender: Oxygen Biotherapeutics Inc.
EANS-Adhoc: Oxygen Biotherapeutics Reports Financial Results For Third Quarter FY2011
OTS0004 | 22. März 2011, 06:54 | Channel: Finanzen | Aussender: Oxygen Biotherapeutics Inc.
EANS-Adhoc: Oxygen Biotherapeutics and Hackensack University Medical Center Sign Research Contract Funded by the U.S. Department of Defense to Study Wound Healing Properties of Wundecyte™ Gel
OTS0005 | 28. Jan. 2011, 06:31 | Channel: Finanzen | Aussender: Oxygen Biotherapeutics Inc.
EANS-Adhoc: Oxygen Biotherapeutics Inc. / US-Verteidigungsministerium finanziert Wundecyte-Studie
OTS0004 | 28. Jan. 2011, 06:31 | Channel: Finanzen | Aussender: Oxygen Biotherapeutics Inc.
